has such a profound and specific effect on immunocompetence, is somewhat surprising. It might have been expected that the elimination of a regulator of quiescence would have led to hyperactive immune responses and even autoimmunity. Likewise, the relative specificity of the Slfn2 mutation is intriguing. It affects T cells and monocytes but not natural killer cells or B cells. It affects specific T cell antigen receptor-induced signaling pathways while having no effect on others. In this context, it will be of great interest to decipher the downstream targets responsible for mediating Slfn2 function.
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viruses have learned to manipulate Schlafen function for their own purposes 11 . The electra mutation turns out to be a thymidine-to-adenosine transversion in Slfn2 that leads to an isoleucine-to-asparagine substitution at position 135 of Slfn2. At this time, the region in which the substitution is located has no known or predicted function. Indeed, the precise mechanism by which Slfn2 mediates its inhibitory effect has yet to be determined; however, some clues exist. First, although elektra mice show normal activation of the signaling pathways of the transcription factors NFAT and NF-κB and the kinases Erk and Akt, the mitogen-activate protein kinases p38 and Jnk are constitutively phosphorylated, even under basal conditions (Fig. 1) . Second, expression of the antiapoptotic factor Bcl-2 is specifically lower in T cells from the elektra mice. Transgenic expression of Bcl-2 prevents the apoptosis seen in CD4 + and CD8 + T cells from elektra mice. However, Bcl-2 expression is not able to prevent the semiactivated state of these cells.
The study of Berger et al. 1 demonstrates the potential power of N-ethyl-N-nitrosoureainduced mutational screening. The finding that the immunodeficiency seen in the elektra mice is due to a mutation in a gene that is a member of a gene family with as-yet-unclearly defined function opens many new avenues in terms of exploring regulation of immune responses. Indeed, the finding that the Slfn2 mutation disrupts quiescence, which in turn Smad3 as well as those of the Foxo family and Tob, have been linked to the maintenance of quiescence, controversy exists regarding their exact roles [2] [3] [4] [5] [6] [7] . This confusion stems from the ability of these molecules to regulate global cellular processes independently of quiescence, such as apoptosis and survival. For example, Tob, a member of the APRO (antiproliferative) family of proteins, can interact with the Smad proteins to regulate the transcription of genes involved in both the induction and the inhibition of cell growth 6 . Also, in T cells, Tob1 is downregulated by engagement of the T cell antigen receptor in the context of costimulation and has been suggested to be involved in T cell anergy.
The elektra mutation identifies another participant in the maintenance of quiescence 1 . Slfn2 is one of nine members of the Schlafen family of genes clustered on mouse chromosome 11. These genes were first described in mice as being transcribed during thymocyte development and have been linked to the regulation of cell growth and differentiation 8 . Subsequently, they have been shown to be variably expressed in effector and regulatory T cells, as well as macrophages 9, 10 . Although it is clear that these genes are expressed differently in cells of hematopoietic origin, their precise function has yet to be determined. Adding to the mystery of this gene family is the fact that many orthopoxviruses contain homologs of Schlafen genes, which suggests that these D uring inflammation, flowing neutrophils tether to and roll on vascular surfaces by reversible binding of P-, L-and E-selectin to glycosylated ligands 1, 2 . One of the earliest events is mobilization of P-selectin from secretory granules to the surfaces of endothelial cells and platelets after activation by thrombin, complement and other mediators. P-selectin initiates rolling by interacting with the transmembrane mucin PSGL-1 on neutrophils. Rolling permits selectin ligands and chemokine receptors on neutrophils to signal integrin-dependent deceleration, arrest and, ultimately, immigration into infected or injured tissues 3 . Whereas the mediators that trigger inflammation have been studied extensively, less is known about the mechanisms that limit inflammation. In this issue of Nature Immunology, Mantovani and colleagues report that the pentraxin PTX3, a protein known to augment innate immunity, also dampens neutrophil recruitment in vivo 4 . PTX3 binds to P-selectin and may limit inflammation by inhibiting the rolling of neutrophils on P-selectin.
PTX3 is an evolutionarily conserved, multimeric protein 5 . Cytokines and endotoxins induce endothelial cells, macrophages and dendritic cells to synthesize PTX3, and neutrophils store PTX3 in specific granules. Like antibodies, PTX3 binds to pathogens, activates complement and opsonizes particles. However, overexpression of PTX3 in mice increases resistance to lipopolysaccharide challenge 6 , and PTX3-deficient mice are more susceptible to ischemia-reperfusion injury 7 . The mechanism for these anti-inflammatory effects of PTX3 has remained unclear. The new work demonstrates that PTX3 diminishes the number of neutrophils rolling on P-selectin. Furthermore, nature immunology volume 11 number 4 april 2010 it to bind with greater avidity to P-selectin. Mantovani and colleagues use surface plasmon resonance to measure binding of soluble P-selectin to immobilized recombinant PTX3 (ref. 4) . The data suggest that P-selectin binds with slower on-and off-rates to PTX3 than to PSGL-1. This conclusion should be considered tentative, as soluble P-selectin is not confirmed to be monomeric and PTX3 is immobilized at high concentrations that could permit dissociating P-selectin to rebind.
In vitro, PTX3 decreases the number of neutrophils rolling on P-selectin in a concentration-dependent manner. Competitively inhibiting P-selectin-PSGL-1 bonds should increase the velocities of residual rolling cells by decreasing the number of bonds. However, the effects of PTX3 on rolling velocities are not reported here. In vivo, injection of PTX3 results in fewer neutrophils rolling in thrombin-activated post-capillary venules in the mesentery. Surprisingly, PTX3 has no effect on the velocity distributions of the residual rolling cells. This by soluble PSGL-1 and by a monoclonal antibody to P-selectin that blocks binding to PSGL-1. Instead of binding directly to P-selectin, the N-glycan on recombinant PTX3 might positively regulate the conformation of the C-terminal domain to favor protein-protein interactions with P-selectin. Consistent with that possibility, heat treatment of recombinant PTX3 blocks its anti-inflammatory effects; heating typically alters protein rather than glycan conformation. A specific proteinprotein interaction might explain the authors' observation that recombinant PTX3 binds to P-selectin but not to L-or E-selectin. Less neutrophil-derived PTX3 than recombinant PTX3 is needed to detect binding to immobilized P-selectin, perhaps because neutrophils express an sLe X -capped N-glycan on the C-terminal domain of PTX3. P-selectin might bind cooperatively to glycan and protein components of neutrophil-derived PTX3, as it does to PSGL-1. Alternatively, neutrophils might store PTX3 as larger multimers in specific granules, enabling administration of PTX3 to mice inhibits acidinduced recruitment of neutrophils to the lungs or chemokine-induced entry of neutrophils into the pleural cavity to the same extent as antibody blockade or genetic deficiency in P-selectin.
Each subunit of PTX3 has an N-terminal domain linked to a C-terminal domain related to those of other pentraxins 5 . The C-terminal domain binds to the complement protein C1q and other known ligands of PTX3. It has a single sialylated, complex N-glycan attached to Asn220. Enzymatic removal of the glycan or site-directed mutagenesis of Asn220 to prevent attachment of the glycan enhances binding of the C-terminal domain to C1q and other known ligands 5 . This suggests that the glycan negatively regulates the conformation or accessibility of the ligand-binding surface of PTX3. Mantovani and colleagues show that the PTX3 C-terminal domain also interacts with P-selectin 4 . Whereas removal of the N-glycan results in more binding to other ligands, it results in less binding to P-selectin. The authors conclude that PTX3 uses this glycan to bind directly to P-selectin, but if so, the binding must be quite different from that of known glycan ligands for selectins. To mediate rolling, the N-terminal lectin domain of each selectin binds in a Ca 2+ -dependent manner to a small number of membrane glycoproteins. The essential, common recognition determinant on these glycoproteins is sialyl Lewis X (sLe X ; (sialyl-(α2-3)-galactopyranosyl-( β 1 -4 ) -[ f u c o p y r a n o s y l -( α 1 -3 ) ] -Nacetylglucosaminylpyranosyl-(β1-R))), a terminal component of some N-and O-glycans 2 . A Ca 2+ ion that coordinates residues in a loop in the lectin domain also makes contacts with the α1-3-linked fucose in the sLe X determinant, which explains the Ca 2+ dependency of binding 8 . Mantovani and colleagues do not examine the Ca 2+ dependency of the binding of P-selectin to PTX3. For nearly all experiments, the authors use recombinant PTX3 expressed in Chinese hamster ovary cells 4 . These cells lack the α1-3-fucosyltransferases that attach fucose to form the sLe X determinant 9 . Indeed, published structural analysis of the N-glycan on recombinant PTX3 has shown core α6-linked fucose but no terminal α3-linked fucose 10 .
Importantly, P-selectin 'preferentially' binds to PSGL-1 because it also recognizes non-glycan determinants. A broad surface of the lectin domain interacts cooperatively with sulfated tyrosines, adjacent amino acids and an sLe X -capped O-glycan, all clustered near the PSGL-1 N terminus 8 . PSGL-1 and PTX3 may bind to overlapping sites on P-selectin, as binding of PTX3 to P-selectin is inhibited Blood f flow Blood Figure 1 Model for PTX3's paracrine regulation of neutrophil rolling on P-selectin. (a) Interactions of PSGL-1 on neutrophils with P-selectin on activated endothelial cells mediate rolling in venules at sites of infection or injury. Rolling neutrophils release PTX3 from specific granules. PTX3 binds to locally expressed P-selectin, which prevents subsequent interactions with PSGL-1. (b) As PTX occupies more P-selectin molecules, neutrophils tether less frequently, roll faster with less stability and detach rather than arrest. dent leukocyte adhesion. These proteins may act together with other anti-inflammatory systems, such as activation of protein C, a serine protease, by the thrombin-thrombomodulin complex on endothelial cell surfaces 13 . The findings of Mantovani and colleagues underscore the delicate balance between initiating inflammation to contain microbial invasion and dampening inflammation to prevent untoward tissue injury 4 . Defining natural mechanisms that check neutrophil recruitment may offer new approaches for treating inflammatory diseases.
and enhances detachment. The magnitude of adhesion inhibition will depend on the number of P-selectin molecules that PTX3 occupies. Variants of the model are possible. For example, release of PTX3 might require that neutrophils engage chemokine receptors or receive outside-in signals through integrins after they arrest or begin to crawl toward endothelial cell junctions. Neutrophils interacting with P-selectin on activated platelets might deploy PTX3 in a similar paracrine loop. Mantovani and colleagues suggest that widespread inflammation such as sepsis could generate high concentrations of circulating PTX3 with systemic anti-inflammatory effects 4 . In this scenario, activated endothelial cells, dendritic cells and/ or macrophages may be major sources of PTX3. The new work demonstrates that PTX3 inhibits P-selectin-dependent adhesion, but other stillundefined mechanisms could contribute to its anti-inflammatory properties in vivo. PTX3 is the second described endogenous inhibitor of leukocyte adhesion to vascular surfaces. The first is Del-1, a glycoprotein secreted by endothelial cells that associates with the cell surface 12 . Del-1 binds to the leukocyte integrin α L β 2 . But rather than promoting α L β 2 -dependent adhesion, Del-1 inhibits adhesion by competitively inhibiting the binding of α L β 2 to ICAM-1, a well-characterized integrin ligand on endothelial cells 12 . Thus, distinct endogenous proteins limit inflammation by inhibiting either selectin-or integrin-depenobservation is difficult to reconcile with the idea that PTX3 acts by competitively inhibiting P-selectin. Selectin-specific antibodies are not used to define the rolling interactions. The discrepancy could be explained if neutrophils rolled on E-as well as P-selectin in the mesenteric venules. In tumor necrosis factoractivated venules of the cremaster muscle, neutrophils roll on both E-and P-selectin, and E-selectin governs mainly rolling velocities 11 .
What is the source of the anti-inflammatory PTX3? By transplanting wild-type or PTX3-deficient bone marrow into irradiated wild-type or PTX3-deficient recipient mice, Mantovani and colleagues show that PTX3 from hematopoietic cells is needed to suppress neutrophil recruitment into the pleural cavity in the first 2 hours after chemokine challenge 4 . In this short time frame, neutrophils are the likely source of PTX3, as they are the only hematopoietic cells that store PTX3. The data suggest a testable model (Fig. 1) . Neutrophils rolling on P-selectin in venules at sites of infection or injury receive signals that release PTX3 from specific granules. The released PTX3 binds to locally expressed P-selectin in a paracrine manner. The multimeric nature of PTX3 increases binding avidity that slows dissociation from P-selectin. As more neutrophils roll, they release more PTX3, which occupies more P-selectin molecules. This constitutes a local, negative feedback system that diminishes neutrophil tethering, accelerates rolling ross-presentation is a highly coordinated mechanism that permits dendritic cells (DCs) to present exogenous antigens to CD8 + T cells. But despite all of the energy invested in antigen uptake, transport to the cytosol, processing and presentation onto major histocompatibility complex class I, this represents only one of the signals needed to achieve T cell priming. Indeed, present thought suggests that three signals-aptly referred to as signal 1, signal 2 and signal 3-are required for crosspriming of an antigen-specific CD8 + T cell by a DC. Signal 1 constitutes the complex of peptide and major histocompatibility complex class I that engages the TCR; signal 2 refers to costimulatory molecules such as B7-family members that ligate CD28; and signal 3 signifies the soluble factors needed to overcome tolerance signals and induce priming (for example, interleukin 12 and interferon-α/β). Although DCs seem to be able to deliver all three classes of stimulation to a responding CD8 + T cell, growing evidence suggests that under physiological and pathophysiological conditions, they require help. Classically, such help is thought to be delivered by CD4 + T cells, but other cell types, including plasmacytoid DCs and natural killer T (NKT) cells, can also do the job 1,2 . In addition to stimulating DCs to secrete signal 3 inflammatory cytokines, helper cells may also participate in creating a chemokine gradient that enhances the recruitment of CD8 + T cells, effectively increasing the probability that DCs will encounter effector cells. In this issue of Nature Immunology, Semmling et al. characterize the mechanism of NKT cell help and add to the list of chemokines that can promote DC-CD8 + T cell interactions, thus enhancing cross-priming 3 . We propose that such signals should be referred to as 'signal 0' , as they act upstream of the DC-T cell contact and guide the priming of cytotoxic T lymphocytes, and here we discuss the benefit but also the risk
